Beneficial effect of human anti-amyloid-β active immunization on neurite morphology and tau pathology

Brain

Volumn 133, Issue 5, 2010, Pages 1312-1327

  Serrano Pozo, Alberto ^a,b   William, Christopher M ^a   Ferrer, Isidro ^c   Uro Coste, Emmanuelle ^d   Delisle, Marie Bernadette ^d   Maurage, Claude Alain ^e   Hock, Christoph ^f   Nitsch, Roger M ^f   Masliah, Eliezer ^g   Growdon, John H ^a   Frosch, Matthew P ^a   Hyman, Bradley T ^a  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b HOSPITAL UNIVERSITARIO VIRGEN DEL ROCÍO   (Spain)

^c HOSPITAL UNIVERSITARI DE BELLVITGE   (Spain)

^d TOULOUSE UNIVERSITY HOSPITAL   (France)

^e UNIV LILLE   (France)

^f UNIVERSITY OF ZURICH   (Switzerland)

^g UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Alzheimer's disease; Amyloid; AN1792; Immunization

Indexed keywords

ALZHEIMER DISEASE VACCINE; AMYLOID BETA PROTEIN ANTIBODY; AMYLOID PROTEIN; DIRECT YELLOW 7; TAU PROTEIN; THIOFLAVINE; UNCLASSIFIED DRUG;

AGED; ALZHEIMER DISEASE; ARTICLE; ASTROCYTE; ASTROCYTOSIS; BRAIN MITOCHONDRION; CELL STRUCTURE; CLINICAL ARTICLE; CONTROLLED STUDY; DYSTROPHY; FEMALE; HIPPOCAMPUS; HUMAN; HUMAN TISSUE; IMMUNIZATION; MALE; NEURITE; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; QUANTITATIVE ANALYSIS;

EID: 77951893095     PISSN: 00068950     EISSN: 14602156     Source Type: Journal    
DOI: 10.1093/brain/awq056     Document Type: Article

References (53)

1. Akiyama H, Tago H, Itagaki S, McGeer PL. Occurrence of diffuse amyloid deposits in the presubicular parvopyramidal layer in Alzheimer's disease. Acta Neuropathol 1990; 79: 537-544
2. Augustinack JC, Schneider A, Mandelkow EM, Hyman BT. Specific tau phosphorylation sites correlate with severity of neuronal cytopathology in Alzheimer's disease. Acta Neuropathol 2002; 103: 26-35.
3. Bacskai BJ, Kajdasz ST, Christie RH, Carter C, Games D, Seubert P, et al. Imaging of amyloid-b deposits in brains of living mice permits direct observation of clearance of plaques with immunotherapy. Nat Med 2001; 7: 369-372
4. Bacskai BJ, Kajdasz ST, McLellan ME, Games D, Seubert P, Schenk D, et al. Non-Fc-mediated mechanisms are involved in clearance of amyloid-b in vivo by immunotheraphy. J Neurosci 2002; 22: 7873-7878
5. Bard F, Cannon C, Barbour R, Burke RL, Games D, Grajeda H, et al. Peripherally administered antibodies against amyloid b-peptide enter the central nervous system and reduce pathology in a mouse model of Alzheimer disease. Nat Med 2000; 6: 916-919
6. Boche D, Zotova E, Weller RO, Love S, Neal JW, Pickering RM, et al. Consequence of Ab immunization on the vasculature of human Alzheimer's disease brain. Brain 2008; 131: 3299-3310
7. Bombois S, Maurage CA, Gompel M, Deramecourt V, Mackowiak-Cordoliani MA, Black RS, et al. Absence of b-amyloid deposits after immunization in Alzheimer disease with Lewy body dementia. Arch Neurol 2007; 64: 583-587
8. Braak H, Braak E. Neuropathological stageing of Alzheimer-related changes. Acta Neuropathol 1991; 82: 239-259
9. Brendza RP, Bacskai BJ, Cirrito JR, Simmons KA, Skoch JM, Klunk WE, et al. Anti-Ab antibody treatment promotes the rapid recovery of amyloid-associated neuritic dystrophy in PDAPP transgenic mice. J Clin Invest 2005; 115: 428-433
10. Buttini M, Masliah E, Barbour R, Grajeda H, Motter R, Johnson-Wood K, et al. b-amyloid immunotherapy prevents synaptic degeneration in a mouse model of Alzheimer's disease. J Neurosci 2005; 25: 9096-9101 (Pubitemid 41500817)
11. Carmel G, Mager EM, Binder LI, Kuret J. The structural basis of monoclonal antibody Alz50's selectivity for Alzheimer's disease pathology. J Biol Chem 1996; 51: 32789-32795
12. Carulla N, Caddy GL, Hall DR, Zurdo J, Gairi M, Feliz M, et al. Molecular recycling within amyloid fibrils. Nature 2005; 436: 554-558
13. Cruz L, Urbanc B, Buldyrev SV, Christie R, Gó mez-Isla T, Havlin S, et al. Aggregation and disaggregation of senile plaques in Alzheimer disease. Proc Natl Acad Sci 1997; 94: 7612-7616
14. D'Amore JD, Kajdasz ST, McLellan ME, Bacskai BJ, Stern EA, Hyman BT. In vivo multiphoton imaging of a transgenic mouse model of Alzheimer disease reveals marked thioflavin-S-associated alterations in neurite trajectories. J Neuropathol Exp Neurol 2003; 62: 137-145
15. DeKosky ST, Scheff SW. Synapse loss in frontal cortex biopsies in Alzheimer's disease: Correlation with cognitive severity. Ann Neurol 1990; 27: 457-464
16. DeMattos RB, Bales KR, Cummins DJ, Dodart JC, Paul SM, Holtzman DM. Peripheral anti-Ab antibody alters CNS and plasma Ab clearance and decreases brain Ab burden in a mouse model of Alzheimer's disease. Proc Natl Acad Sci 2001; 98: 8850-8855
17. Dodart JC, Bales KR, Gannon KS, Greene SJ, DeMattos RB, Mathis C, et al. Immunization reverses memory deficits without reducing brain Ab burden in Alzheimer's disease model. Nat Neurosci 2002; 5: 452-457
18. Ferrer I, Boada-Rovira M, Sá nchez-Guerra ML, Rey MJ, Costa-Jussá F. Neuropathology and pathogenesis of encephalitis following amyloid-b immunization in Alzheimer's disease. Brain Pathol 2004; 14: 11-20.
19. Fiala JC, Feinberg M, Peters A, Barbas H. Mitochondrial degeneration in dystrophic neurites of senile plaques may lead to extracellular deposition of fine filaments. Brain Struct Funct 2007; 212: 195-207.
20. Gilman S, Koller M, Black RS, Jenkins L, Griffith SG, Fox NC, et al. Clinical effects of Ab immunization (AN1792) in patients with AD in an interrupted trial. Neurology 2005; 64: 1553-1562
21. Gó mez-Isla T, Price JL, McKeel DW Jr, Morris JC, Growdon JH, Hyman BT. Profound loss of layer II entorhinal cortex neurons occurs in very mild Alzheimer's disease. J Neurosci 1996; 16: 4491-4500
22. Gó mez-Isla T, Hollister R, West H, Mui S, Growdon JH, Petersen RC, et al. Neuronal loss correlates with but exceeds neurofibrillary tangles in Alzheimer's disease. Ann Neurol 1997; 41: 17-24.
23. Hardy J, Selkoe DJ. The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics. Science 2002; 297: 353-356
24. Hock C, Konietzko U, Streffer JR, Tracy J, Signorell A, Mü ller-Tillmanns B, et al. Antibodies against b-amyloid slow cognitive decline in Alzheimer's disease. Neuron 2003; 38: 547-554
25. 42 immunisation in Alzheimer's disease: follow-up of a randomised, placebo-controlled phase I trial. Lancet 2008; 372: 216-223
26. Hyman BT, Gó mez-Isla T, Irizarry MC. Stereology: a practical primer for neuropathology. J Neuropathol Exp Neurol 1998; 57: 305-310
27. Janus C, Pearson J, McLaurin J, Mathews PM, Jiang Y, Schmidt SD, et al. Ab immunization reduces behavioural mathewsimpairment and plaques in a model of Alzheimer's disease. Nature 2000; 408: 979-982
28. Kalus P, Braak H, Braak E, Bohl J. The presubicular region in Alzheimer's disease: topography of amyloid deposits and neurofibrillary changes. Brain Res 1989; 494: 198-203.
29. Kidd M. Alzheimer's disease. An electron microscopical study. Brain 1964; 87: 307-320
30. Knowles RB, Wyart C, Buldyrev SV, Cruz L, Urbanc B, Hasselmo ME, et al. Plaque-induced neurite abnormalities: implications for disruption of neural networks in Alzheimer's disease. Proc Natl Acad Sci 1999; 96: 5274-5279
31. Kotilinek LA, Bacskai B, Westerman M, Kawarabayashi T, Younkin L, Hyman BT, et al. Reversible memory loss in a mouse transgenic model of Alzheimer's disease. J Neurosci 2002; 22: 6331-6335
32. Lee M, Bard F, Johnson-Wood K, Lee C, Hu K, Griffith SG, et al. Ab42 immunization in Alzheimer's disease generates Ab N-terminal antibodies. Ann Neurol 2005; 58: 430-435
33. Lemere CA, Spooner ET, LaFrancois J, Malester B, Mori C, Leverone JF, et al. Evidence for peripheral clearance of cerebral Ab protein following chronic, active Ab immunization in PSAPP mice. Neurobiol Dis 2003; 14: 10-18
34. Lombardo JA, Stern ES, McLellan ME, Kajdasz ST, Hickey GA, Bacskai BJ, et al. Amyloid-b antibody treatment leads to rapid normalization of plaque-induced neuritic alterations. J Neurosci 2003; 23: 10879-10883
35. Martins IC, Kupperstein I, Wilkinson H, Maes E, Vanbrabant M, Jonckheere W, et al. Lipids revert inert Ab amyloid fibrils to neurotoxic protofibrils that affect learning in mice. Embo J 2008; 27: 224-233
36. Masliah E, Hansen L, Adame A, Crews L, Bard F, Lee C, et al. Ab vaccination effects on plaque pathology in the absence of encephalitis in Alzheimer disease. Neurology 2005; 64: 129-131
37. Meyer-Luehmann M, Spires-Jones TL, Prada C, García-Alloza M, de Calignon A, Rozkalne A, et al. Rapid appearance and local toxicity of amyloid-b plaques in a mouse model of Alzheimer's disease. Nature 2008; 451: 720-725
38. Morgan D, Diamond DM, Gottschall PE, Ugen KE, Dickey C, Hardy J, et al. Ab peptide vaccination prevents memory loss in an animal model of Alzheimer's disease. Nature 2000; 408: 982-985
39. Nicoll JAR, Wilkinson D, Holmes C, Steart P, Markham H, Weller RO. Neuropathology of human Alzheimer disease after immunization with amyloid-b peptide: a case report. Nat Med 2003; 9: 448-452
40. Oddo S, Billings L, Kesslak JP, Cribbs DH, LaFerla FM. Ab immunother-apy leads to clearance of early, but not late, hyperphosphorylated tau aggregates via the proteasome. Neuron 2004; 43: 321-332
41. 42 accumulation delays the onset and progression of tau pathology via the C terminus of Heat Shock Protein70-Interacting Protein: a mechanistic link between Ab and tau pathology. J Neurosci 2008; 28: 12163-12175
42. Orgogozo JM, Gilman S, Dartigues JF, Laurent B, Puel M, Kirby LC, et al. Subacute meningoencephalitis in a subset of patients with AD after Ab42 immunization. Neurology 2003; 61: 46-54.
43. Otvos L Jr, Feiner L, Lang E, Szendrei GI, Goedert M, Lee VMY. Monoclonal antibody PHF-1 recognizes tau protein phosphorylated at serine residues 396 and 404. J Neurosci Res 1994; 39: 669-673
44. Patton RL, Kalback WM, Esh CL, Kokjohn TA, Van Vickle GD, Luehrs DC, et al. Amyloid-b peptide remnants in AN-1792-immunized Alzheimer's disease patients. A biochemical analysis. Am J Pathol 2006; 169: 1048-1063
45. Schenk D, Barbour R, Whitney D, Gordon G, Grajeda H, Guido T, et al. Immunization with amyloid-b attenuates Alzheimer-disease-like pathology in the PDAPP mouse. Nature 1999; 400: 173-177
46. Spires-Jones TL, Mielke ML, Rozkalne A, Meyer-Luehmann M, de Calignon A, Bacskai BJ, et al. Passive immunotheraphy rapidly increases structural plasticity in a mouse model of Alzheimer disease. Neurobiol Dis 2009; 33: 213-220
47. Stern EA, Bacskai BJ, Hickey GA, Attenello FJ, Lombardo JA, Hyman BT. Cortical synaptic integration in vivo is disrupted by amyloid-b plaques. J Neurosci 2004; 24: 4535-4540
48. Terry RD, Masliah E, Salmon DP, Butters N, DeTeresa R, Hill R, et al. Physical basis of cognitive alterations in Alzheimer's disease: synapse loss is the major correlate of cognitive impairment. Ann Neurol 1991; 30: 572-580
49. Uro-Coste E, Russano de Paiva G, Guilbeau-Frugier C, Sastre N, Ousset PJ, Adolfo da Silva N, et al. Cerebral amyloid angiopathy and microhaemorrhages after amyloid b vaccination: case report and brief review. Clin Neuropathol 2010 in press.
50. Vellas B, Black R, Thal LJ, Fox NC, Daniels M, McLennan G, et al. Long-term follow-up of patients immunized with AN1792: reduced functional decline in antibody responders. Curr Alzheimer Res 2009; 6: 144-151
51. Wilcock DM, Rojiani A, Rosenthal A, Levkowitz G, Subbarao S, Alamed J, et al. Passive amyloid immunotherapy clears amyloid and transiently activates microglia in a transgenic mouse model of amyloid deposition. J Neurosci 2004; 24: 6144-6151
52. Wilcock DM, Gharkholonarche N, Van Nostrand WE, Davis J, Vitek MP, Colton CA. Amyloid reduction by amyloid-b vaccination also reduces mouse tau pathology and protects from neuron loss in two mouse models of Alzheimer's disease. J Neurosci 2009; 29: 7957-7965
53. Wisniewski HM, Sadowski M, Jakubowska-Sadowska K, Tarnawski M, Wegiel J. Diffuse, lake-like amyloid-b deposits in the parvopyramidal layer of the presubiculum in Alzheimer disease. J Neuropathol Exp Neurol 1998; 57: 674-683